Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia - Concepedia

Concepedia

Publication | Closed Access

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

547

Citations

45

References

2007

Year

Agustin A. García, Hal W. Hirte, Gini F. Fleming, Dongyun Yang, Denice Tsao‐Wei, Lynda D. Roman, Susan Groshen, Steve Swenson, Frank Markland, David R. Gandara,

Journal of Clinical Oncology

Abstract

The combination of bevacizumab and metronomic cyclophosphamide is active in recurrent OC. Further study of this combination is warranted.

References

	Year	Citations

Page 1